New dual-target cell therapy takes on hard-to-treat lymphoma
NCT ID NCT07508605
First seen Apr 10, 2026 · Last updated Apr 22, 2026 · Updated 1 time
Summary
This study tests a new treatment for people with B-cell lymphoma that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to target two markers on cancer cells. The goal is to control the disease, not cure it. About 20 adults aged 18-75 will receive one infusion of these cells after a short chemotherapy course.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen University General Hospital
RECRUITINGShenzhen, Guangdong, 518055, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.